FABP3 and peripheral arterial disease: In this scenario, an increase in acute circulatory FABP3 may be beneficial, for example, after acute myocardial infarction; however, a chronic presence of circulatory FABP3 in PAD patients may be beneficial for similar reasons but is countered by the detrimental additive effect to increase the severity of PAD.